San Jose BioCenter

ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD

Retrieved on: 
Thursday, November 16, 2023
Food and Drug Administration, Safety, Food, Plasma, Collection, Commerce, FDA, Marketing, San Jose BioCenter, ADMA

RAMSEY, N.J. and BOCA RATON, Fla. and LAUREL, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its tenth ADMA BioCenters plasma collection facility located in Laurel, Maryland.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla. and LAUREL, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its tenth ADMA BioCenters plasma collection facility located in Laurel, Maryland.
  • This plasma collection facility commenced operations and initiated source plasma collection in the first half of 2023.
  • The approval is a testament to the BioCenters team’s tireless commitment, and we thank the FDA for its efforts and expeditious review of the Laurel, MD Biologics License Application (“BLA”),” said Adam Grossman, President and Chief Executive Officer of ADMA.
  • This center is approved to use the state-of-the-art Haemonetics NexSys Persona® plasma collection system.

ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
Adjustment, FDA, Growth, Immunodeficiency, Plasma, FY, Abu Dhabi Medical Congress, Food, PIN, RVI, Urinary tract infection, Mortality, EBITDA, Conference, Biopharma LLC, GAAP, Doctor of Philosophy, Net income, Licensure, Borescope, Marketing, Master of Science, Total revenue, Infection, ADMA, Collection, Patient, Food and Drug Administration, Increase, San Jose BioCenter, Bookkeeping, Fine chemical, Pharmaceutical industry, Beauty salon, Video game, MD

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its third quarter 2023 financial results and provided a business update.
  • Third Quarter 2023 Milestones & Objectives:
    Increased Revenue Guidance for Full Years (FY) 2023, 2024, and 2025.
  • 2023 & Long-Term Financial Guidance:
    Updated 2023 Financial Guidance: ADMA now anticipates FY 2023 total revenues to exceed $250 million, increased from $240 million previously.
  • As a result, ADMA achieved a gross margin of 36.6% in the third quarter of 2023 as compared to 23.5% in the third quarter of 2022.

ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 9, 2023
Morgan Stanley, Total revenue, PI, Marketing, Infection, Food and Drug Administration, ADMA, Quality of life, Licensure, Net, CIS, GAAP, Plasma, IG, EBITDA, PIN, Patient, Collection, Risk, Primary immunodeficiency, Bronchiectasis, Growth, Yoy, IVIG, San Jose BioCenter, FDA, Conference, Food, RVI, Fine chemical, Video game, Pharmaceutical industry, Bookkeeping, Bank, Beauty salon, Cryptocurrency, Adjustment

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its second quarter 2023 financial results and provided a business update.
  • Driven by 77% year-over-year revenue growth, which reached $60.1 million during the second quarter of 2023, ADMA grew Adjusted EBITDA to $6.4 million.
  • 2023 & Long-Term Financial Guidance:
    Updated 2023 Financial Guidance: ADMA now anticipates full year 2023 total revenues to meet or exceed $240 million, increased from $220 million previously.
  • As a result, ADMA achieved a gross margin of 27.8% in the second quarter of 2023 as compared to 22.9% in the second quarter of 2022.

ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

Retrieved on: 
Wednesday, July 19, 2023
Marketing, Food and Drug Administration, ADMA, Suite, Plasma, Collection, Commerce, San Jose BioCenter, FDA, Food, Safety, Pharmaceutical industry, DALLAS

RAMSEY, N.J. and BOCA RATON, Fla. and DALLAS, Ga., July 19, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its ninth ADMA BioCenters plasma collection facility located in Dallas, GA. This plasma collection facility commenced operations and initiated source plasma collection in the third quarter of 2022. With the FDA approval announced today, this facility is now licensed to collect, and introduce into interstate commerce, human source plasma for further manufacturing in the U.S.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla. and DALLAS, Ga., July 19, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its ninth ADMA BioCenters plasma collection facility located in Dallas, GA.
  • This plasma collection facility commenced operations and initiated source plasma collection in the third quarter of 2022.
  • “With nine FDA-licensed plasma collection centers, we are well on our way to achieving our stated corporate objective of having a total of ten FDA-approved plasma collection centers, collecting normal source plasma and hyperimmune plasma, by year-end 2023,” said Brian Lenz, Executive Vice President, Chief Financial Officer, and General Manager, ADMA BioCenters.
  • This center is approved to use the state-of-the-art Haemonetics NexSys Persona® plasma collection system.

ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 10, 2023
Morgan Stanley, Total revenue, Marketing, Food and Drug Administration, ADMA, Licensure, Cost of capital, Plasma, EBITDA, Publication, PIN, Patient, Collection, Cost, Acquisition, Antibody, Growth, Security (finance), San Jose BioCenter, FDA, Conference, Food, Video game, Pharmaceutical industry, Bookkeeping, Beauty salon, Bank, Adjustment

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its first quarter 2023 financial results and provided a business update.
  • “ADMA generated first-time Adjusted EBITDA profitability, totaling $2.5 million, during the first quarter of 2023.
  • 2023 & Long-Term Financial Guidance:
    2023 Financial Guidance: ADMA now anticipates full year 2023 total revenues to exceed $220 million.
  • Additionally, during the first quarter of 2023, ADMA sold a significant amount of the remaining 2,200-liter scale, lower margin BIVIGAM product.

ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 23, 2023
Morgan Stanley, Total revenue, Marketing, Food and Drug Administration, ADMA, Licensure, Plasma, IG, EBITDA, PIN, Publication, Patient, Collection, Average cost, IVIG, Growth, San Jose BioCenter, FDA, Conference, Food, Airline, Pharmaceutical industry, Video game, Cryptocurrency, Antibody

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., March 23, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2022 financial results and provided a business update.
  • 2023 & Long-Term Financial Guidance:
    2023 Financial Guidance: ADMA anticipates full year 2023 total revenues to exceed $210 million.
  • Fourth Quarter 2022 Financial Results:
    Total revenues for the quarter ended December 31, 2022 were $50.0 million, as compared to $26.4 million during the fourth quarter of 2021, an increase of $23.6 million, or approximately 90%.
  • Gross profit for the fourth quarter of 2022 was $14.2 million, compared to gross profit of $3.5 million for the fourth quarter of 2021.

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

Retrieved on: 
Wednesday, February 8, 2023
Marketing, Food, Food and Drug Administration, Safety, San Jose BioCenter, ADMA, Collection, FDA, Commerce, Plasma, Pharmaceutical industry

RAMSEY, N.J. and BOCA RATON, Fla. and HAMMOND, La., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its eighth ADMA BioCenters plasma collection facility located in Hammond, Louisiana. This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2022. With the FDA approval announced today, this facility is now licensed to collect, and introduce into interstate commerce, human source plasma for further manufacturing in the U.S.

Key Points: 
  • RAMSEY, N.J. and BOCA RATON, Fla. and HAMMOND, La., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its eighth ADMA BioCenters plasma collection facility located in Hammond, Louisiana.
  • This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2022.
  • “With eight FDA-licensed plasma collection centers, we are well on our way to achieving our stated corporate objective of having a total of ten FDA-approved plasma collection centers, collecting normal source plasma and Respiratory Syncytial Virus (“RSV”) hyperimmune plasma, by year-end 2023,” said Brian Lenz, Executive Vice President, Chief Financial Officer, and General Manager, ADMA BioCenters.
  • This center is approved to use the state-of-the-art Haemonetics NexSys Persona® plasma collection system.

ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 9, 2022
Wiskott–Aldrich syndrome, Increase, Transplant, Risk, Sale, Infection, Virus, Company, Conference, San Jose BioCenter, 8-K, Review, Immunity, Forward-looking statement, Plasma, Morgan Stanley, Marketing, RSV, Environment, IVIG, SEC, Immunodeficiency, Collection, U.S. Securities and Exchange Commission, Research, Patient, Private Securities Litigation Reform Act, Protein, PIDD, Hepatitis B virus, Nasdaq, Food and Drug Administration, Antibody, European Patent Office, Bacteria, Growth, FDA, Income, GLOBE, Respiratory syncytial virus, Sex linkage, PIN, Investment, Federation of Clinical Immunology Societies, Publication, Disease, General manager, ADMA, Urinary tract infection, Iron ore, Pharmaceutical industry, Video game, Vaccine, Medical device, Reinsurance, Air cargo, PI

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its third quarter 2022 financial results and provided a business update.
  • Third Quarter 2022 and Recent Achievements:
    Significant Revenue Growth: Achieved third quarter 2022 total revenues of $41.1 million, as compared to $20.7 million during the third quarter of 2021, an increase of $20.4 million, or approximately 99%.
  • 2022 & Long-Term Financial Guidance:
    2022 Financial Guidance: Enabled by the strong year-to-date execution, ADMA anticipates total 2022 revenues will reach approximately $145 million.
  • Third Quarter 2022 Financial Results:
    Total revenues for the third quarter ended September 30, 2022 were $41.1 million, as compared to $20.7 million during the third quarter of 2021, an increase of $20.4 million, or approximately 99%.

ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

Retrieved on: 
Monday, October 31, 2022
Safety, Marketing, Collection, SC, Food, Food and Drug Administration, 8-K, ADMA, Private Securities Litigation Reform Act, Immunodeficiency, Forward-looking statement, Commerce, U.S. Securities and Exchange Commission, Patient, San Jose BioCenter, Immunity, General manager, Risk, Hepatitis B virus, Suite, European Patent Office, Infection, GLOBE, Plasma, NASDAQ, FDA, Licensure, Environment, Pharmaceutical industry, Medical device, PI

RAMSEY, N.J., BOCA RATON, Fla. and Myrtle Beach, SC. , Oct. 31, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its seventh ADMA BioCenters plasma collection facility located in Greensboro, North Carolina. This plasma collection facility commenced operations and initiated source plasma collection in the first quarter of 2022. With the approval announced today, this facility is now FDA-approved to collect and introduce into interstate commerce, human source plasma for further manufacturing in the U.S.

Key Points: 
  • , Oct. 31, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (FDA) approval for its seventh ADMA BioCenters plasma collection facility located in Greensboro, North Carolina.
  • This plasma collection facility commenced operations and initiated source plasma collection in the first quarter of 2022.
  • The successful expansion of ADMAs plasma collection network supports the Companys goal of plasma supply self-sufficiency, ongoing revenue growth objectives, and further supports the pathway towards profitability.
  • ADMA BioCenters is an FDA-licensed facility specializing in the collection of human plasma used to make special medications for the treatment and prevention of diseases.

ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 10, 2022
Shift, U.S. Securities and Exchange Commission, GLOBE, SEC, Patent, Method, Marketing, Patient, PIN, European Patent Office, Infection, Urinary tract infection, Collection, Disease, Metapneumovirus, Sex linkage, Risk, Private Securities Litigation Reform Act, Environment, Respiratory syncytial virus, Increase, Conference, Immunity, San Jose BioCenter, Forward-looking statement, Growth, Income, General manager, ADMA, 8-K, Lists of diseases, IVIG, Morgan Stanley, Coronavirus, Virus, FDA, Antibody, Immunodeficiency, RSV, PIDD, Immunoglobulin therapy, Plasma, Company, Bacteria, Wiskott–Aldrich syndrome, United States Patent and Trademark Office, Protein, Hepatitis B virus, Food and Drug Administration, Adoption, Video game, Renewable energy, Vaccine, Medical device, Tutoring, PI

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (ADMA or the Company), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its second quarter 2022 financial results and provided a business update.
  • Second Quarter 2022 and Recent Achievements:
    Significant Revenue Growth: Achieved second quarter 2022 total revenues of $33.9 million, as compared to $17.8 million during the second quarter of 2021, an increase of $16.1 million, or approximately 90%.
  • 2022 & Long-Term Financial Guidance:
    2022 Financial Guidance: Enabled by the strong start to the year, ADMA anticipates total 2022 revenues will exceed $130 million.
  • Second Quarter 2022 Financial Results:
    Total revenues for the second quarter ended June 30, 2022 were $33.9 million, as compared to $17.8 million during the second quarter of 2021, an increase of $16.1 million, or approximately 90%.